Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Lung cancer is the second most frequently diagnosed cancer and the leading cause of
cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …

Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …

Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …

Answer questions and earn CME/CNE The revision for the eighth edition of the tumor, node,
and metastasis (TNM) classification of lung cancer was based on analyses of the …

Background Individual plasma proteins have been identified as minimally invasive
biomarkers for lung cancer diagnosis with potential utility in early detection. Plasma …